Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making it more scalable. Researchers believe this innovation has the potential to significantly impact global HIV prevention efforts.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research published in The Lancet medical journal. The drug lenacapavir passed a critical Phase I testing trial and now may become a highly-effective and convenient form of HIV prevention.

Gilead Sciences' data on two novel, once-yearly formulations of lenacapavir for PrEP support the further development of the drug.

If future trials go well - now it has passed the first, Phase I, testing hurdle - it could become the longest-acting form of HIV prevention available. Currently, people can take daily pills or sometimes have injections every eight weeks,

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor,